Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Revenue (2019 - 2025)

Revolution Medicines (RVMD) has 6 years of Revenue data on record, last reported at -$11.4 million in Q3 2025.

  • For Q3 2025, Revenue changed N/A year-over-year to -$11.4 million; the TTM value through Dec 2025 reached -$11.4 million, changed N/A, while the annual FY2023 figure was $11.6 million, 67.27% down from the prior year.
  • Revenue reached -$11.4 million in Q3 2025 per RVMD's latest filing, down from $742000.0 in the prior quarter.
  • Across five years, Revenue topped out at $15.3 million in Q4 2022 and bottomed at -$11.4 million in Q3 2025.
  • Average Revenue over 4 years is $5.4 million, with a median of $7.3 million recorded in 2022.
  • Peak YoY movement for Revenue: soared 204.81% in 2022, then plummeted 95.16% in 2023.
  • A 4-year view of Revenue shows it stood at $9.5 million in 2021, then soared by 62.05% to $15.3 million in 2022, then tumbled by 95.16% to $742000.0 in 2023, then plummeted by 1640.16% to -$11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were -$11.4 million in Q3 2025, $742000.0 in Q4 2023, and $3.8 million in Q2 2023.